ClinicalTrials.gg
RecruitingNCT07503444Updated Nov 2, 2026

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

A Phase 3 interventional study of fenfluramine hydrochloride and Placebo in Rett Syndrome, sponsored by UCB BIOSCIENCES, Inc.. Recruiting at 40 sites in 12 countries. Open to participants aged 5 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 2, 2026First sites in 4 new countries17 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
5 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Rett Syndrome with a site in United States — 11 open to participants now, 21 under way, 5 of them phase 3. Rett Syndrome · United States.

Planned enrollment
2nd of 34
200 · median 32
Started
2026
with 3 others
Phase 3
11 of 55
2 open now
Primary completion
2029-02
later than 16 of 20 live
Registered
53rd of 55
by date

Among the 55 studies in Rett Syndrome with a site in United States, this one is the 2nd largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 11 in phase 3, reaches primary completion later than 16 of the 20 other live ones, and was the 53rd registered.

Rett Syndrome

96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.

Browse Rett Syndrome studies →

Open to participants now

11 of the 55 studies in Rett Syndrome with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: 5 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Rett Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy of fenfluramine hydrochloride (HCl) versus placebo in study participants with Rett syndrome (RTT).

03

Conditions studied

  • Rett Syndrome

Browse trials for

Keywords

  • Fenfluramine HCl
  • RTT
04

Who can participate

Ages eligible
5 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has typical or classic Rett Syndrome (RTT) according to the RettSearch Consortium 2010 revised criteria
  • Participant has a documented disease-causing mutation or deletion in the methyl-CpG-binding protein 2 (MECP2) gene
  • Participant meets criteria for postregression for at least 6 months prior to Screening, defined as:
  • No loss or degradation of ambulation (including gait, coordination, or independence of walking/standing);
  • No loss or degradation of hand function; no loss or degradation of speech (including babbling, words, or previously developed communicative vocalizations);
  • No loss or degradation of nonverbal communicative or social skills (including eye gaze, using body to indicate communicative intent, or social attentiveness)
  • Participant has an Rett Syndrome Clinical Severity Scale (RTT-CSS) rating of 10 to 36 (inclusive)
  • Participant has a Clinical Global Impression-Severity (CGIS) score of ≥4
  • Participant has a legal representative capable of providing signed on behalf of the participant as described in the protocol, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
  • Participant is aged 5 to 35 years of age (inclusive) at the time of first administration of intervention.
  • Male or female.
  • Participant has a consistent caregiver who is ≥18 years of age at the Screening Visit. The caregiver needs to be able to complete the caregiver assessments defined for the entire study. Every attempt should be made to have the same evaluator complete the assessments for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Participant has a history of lymphoma, leukemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years.
  • Participant has abnormality in vital signs according to the Investigator
  • Participant has an exclusionary cardiovascular or cardiopulmonary abnormality based on echocardiogram (ECHO), (ECG), or physical examination, and is not approved for entry by the central cardiac reader. Exclusionary abnormalities include, but are not limited to:

    1. Greater than trace aortic valve regurgitation.
    2. Greater than mild mitral valve regurgitation.
    3. Possible signs of pulmonary arterial hypertension (PAH) with abnormal pulmonary artery systolic pressure (PASP) or PASP ≥35 mmHg.
    4. Evidence of left ventricular dysfunction (systolic or diastolic).
    5. Clinically significant structural cardiac abnormality, including but not limited to mitral valve prolapse, atrial or ventricular septal defects, or patent ductus arteriosus with reversal of shunt (right to left shunt). Note: Patent foramen ovale without a reversal of shunt or a bicuspid aortic valve is not considered exclusionary
  • Participant has a clinically significant medical condition, including , interstitial lung disease, portal hypertension, or need for invasive mechanical ventilation (eg, via tracheostomy), or has had clinically relevant symptoms or a clinically significant illness currently or in the 4 weeks prior to the Screening Visit that would negatively impact study participation, collection of study data, or pose a risk to the participant
  • Participant is taking >4 concomitant antiseizure medications (ASMs). Rescue medications are not included in the count
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    fenfluramine hydrochloride

    Participants will receive fenfluramine hydrochloride for 14 weeks in a double-blind period (including titration and maintenance), followed by a 2-week double-blind transition period. This is followed by a 52-week open-label treatment period. Participants may continue treatment until alternative access is available. Those who discontinue without continued access will undergo an 8-day taper and a 26-week follow-up.

    Drug: fenfluramine hydrochloride

  • Placebo comparator
    Placebo

    Participants will receive a matching placebo for 14 weeks in a double-blind period (including titration and maintenance). After this period, they transition into a 2-week double-blind period with fenfluramine hydrochloride, followed by a 52-week open-label treatment period. Participants may continue treatment until alternative access is available. Those who discontinue without continued access will undergo an 8-day taper and a 26-week follow-up.

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline to Week 14 in Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score

    The RSBQ is a caregiver-completed, instrument assessing behavioral and emotional features in RTT. The RSBQ consists of 45 items, including 8 subscales: General mood (8 items); Breathing problems (5 items); Hand behavior (6 items); Face movements (4 items); Body rocking and expressionless face (6 items); Nighttime behaviors (3 items); Fear/anxiety (4 items); and Walking/standing (2 items). Caregivers are asked to evaluate each RTT feature based on the current status of the patients on a 3-point scale as 0 ("not true"), 1 ("somewhat or sometimes true"), or 2 ("often true"), with the total score ranging from 0 to 90. Higher scores indicate increased disease severity. Seven items that do not belong under any of the subscales are classed as "uncategorized" but contribute to the overall total score.

    Time frame: From Baseline (Day 1) to Week 14

  2. Clinical Global Impression of Change (CGIC) Score at Week 14

    The CGIC is a clinician-rated single item evaluating the degree of improvement or worsening of a participant's condition from Baseline following treatment or intervention. The CGIC uses a 7-point response scale, with the following ratings: "1: Very Much improved", "2: Much improved", "3: Minimally improved", "4: No change", "5: Minimally worse", "6: Much worse", "7: Very Much Worse".

    Time frame: At Week 14

Secondary outcomes

  1. Change from Baseline to Week 14 in Patient-Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) score

    Sleep disturbances will be assessed by the PROMIS-SD parent proxy 8a version. Caregivers are asked to rate 8 items over the past 7 days on a 5-point scale: "1: Never", "2: Almost never", "3: Sometimes", "4: Almost always", and "5: Always", with higher scores indicating more severe sleep disturbances.

    Time frame: From Baseline (Day 1) to Week 14

  2. Change from Baseline to Week 14 in Observer-Reported Communication Ability (ORCA) score

    The ORCA is an 84-item, observer-reported measure of communication ability over the past 30 days. The majority of the items included in the ORCA measure have 3 response options: "No or only once," "Sometimes," and "Yes, almost all the time", which enable derivation of an overall communication score and scores for each form of communication (expressive, receptive, and pragmatic), with higher scores indicating greater communication ability.

    Time frame: From Baseline (Day 1) to Week 14

  3. Caregiver Global Impression of Change - Seizure (CaGIC-Seizure) score at Week 14

    The CaGIC-Seizure is a caregiver-reported item assessing the change from Baseline in the participant's seizure status. The CaGIC-Seizure uses a 7-point response scale, with the following ratings: "1: Very Much improved", "2: Much improved", "3: Minimally improved", "4: No change", "5: Minimally worse", "6: Much worse", "7: Very Much Worse".

    Time frame: At Week 14

  4. Incidence of treatment-emergent adverse events (TEAEs) during the double-blind intervention period

    An AE is any untoward medical occurrence in a clinical study participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment emergent adverse events (TEAEs) are adverse events that are not present prior to the pharmaceutical product administration or an already present event that worsens either in intensity or frequency.

    Time frame: From Baseline (Day 1) up to Week 14

  5. Incidence of serious TEAEs during the double-blind intervention period

    An SAE is defined as any untoward medical occurrence that, at any dose, meets 1 or more of the criteria listed: * Results in death * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.

    Time frame: From Baseline (Day 1) up to Week 14

  6. Incidence of TEAEs leading to discontinuation during the double-blind intervention period

    An AE is any untoward medical occurrence in a clinical study participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment emergent adverse events (TEAEs) are adverse events that are not present prior to the pharmaceutical product administration or an already present event that worsens either in intensity or frequency. TEAEs leading to discontinuation will be reported.

    Time frame: From Baseline (Day 1) up to Week 14

  7. Incidence of related TEAEs during the double-blind intervention period

    An AE is any untoward medical occurrence in a clinical study participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment emergent adverse events (TEAEs) are adverse events that are not present prior to the pharmaceutical product administration or an already present event that worsens either in intensity or frequency. Related TEAEs will be reported.

    Time frame: From Baseline (Day 1) up to Week 14

  8. Change from Baseline in QT interval corrected using Fridericia's formula (QTcF) interval on 12-lead ECG by visit during the double-blind intervention period

    Change from Baseline in QTcF interval as measured by 12-lead ECG up to Week 14 by visit will be reported

    Time frame: From Baseline (Day 1) up to Week 14

  9. Incidence of treatment-emergent Doppler Echocardiogram (ECHO) results meeting the Food and Drug Administration (FDA) case definition of drug-associated valvular heart disease (VHD) during the double-blind intervention period

    The FDA case definition of drug-associated VHD is aortic regurgitation ≥mild and/or mitral regurgitation ≥moderate with restricted valve motion, valve thickening, and/or physical signs or symptoms attributable to valve diseases. ECHO readings related to VHD on any of the 4 valves (aortic, mitral, pulmonary, tricuspid) will be reported with grades of absent, trace, mild, moderate, or severe.

    Time frame: From Baseline (Day 1) up to Week 14

  10. Incidence of treatment-emergent Doppler ECHO results meeting the FDA case definition of PAH (defined as a PASP >35mmHg) during the double-blind intervention period

    ECHO readings related to pulmonary arterial hypertenstion (PAH) will be reported based on Pulmonary artery systolic pressure (PASP).

    Time frame: From Baseline (Day 1) up to Week 14

  11. Incidence of treatment-emergent adverse events (TEAEs) from baseline to end of safety follow up

    An AE is any untoward medical occurrence in a clinical study participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment emergent adverse events (TEAEs) are adverse events that are not present prior to the pharmaceutical product administration or an already present event that worsens either in intensity or frequency.

    Time frame: From Baseline (Day1) to the End of Safety Follow Up (up to 3 years and 10 months)

  12. Incidence of serious TEAEs from baseline to end of safety follow up

    An SAE is defined as any untoward medical occurrence that, at any dose, meets 1 or more of the criteria listed: * Results in death * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.

    Time frame: From Baseline (Day1) to the End of Safety Follow Up (up to 3 years and 10 months)

  13. Incidence of TEAEs leading to discontinuation from baseline to end of safety follow up

    An AE is any untoward medical occurrence in a clinical study participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment emergent adverse events (TEAEs) are adverse events that are not present prior to the pharmaceutical product administration or an already present event that worsens either in intensity or frequency. TEAEs leading to discontinuation will be reported.

    Time frame: From Baseline (Day1) to the End of Safety Follow Up (up to 3 years and 10 months)

  14. Incidence of related TEAEs from baseline to end of safety follow up

    An AE is any untoward medical occurrence in a clinical study participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment emergent adverse events (TEAEs) are adverse events that are not present prior to the pharmaceutical product administration or an already present event that worsens either in intensity or frequency. Related TEAEs will be reported.

    Time frame: From Baseline (Day1) to the End of Safety Follow Up (up to 3 years and 10 months)

  15. Change from Baseline in QT interval corrected using Fridericia's formula (QTcF) interval on 12-lead ECG by visit from baseline to end of safety follow up

    Change from Baseline in QTcF interval as measured by 12-lead ECG up to Week 98 by visit will be reported

    Time frame: From Baseline (Day1) to the End of Safety Follow Up (up to 3 years and 10 months)

  16. Incidence of treatment-emergent Doppler Echocardiogram (ECHO) results meeting the Food and Drug Administration (FDA) case definition of drug-associated valvular heart disease (VHD) from baseline to end of safety follow up

    The FDA case definition of drug-associated VHD is aortic regurgitation ≥mild and/or mitral regurgitation ≥moderate with restricted valve motion, valve thickening, and/or physical signs or symptoms attributable to valve diseases. ECHO readings related to VHD on any of the 4 valves (aortic, mitral, pulmonary, tricuspid) will be reported with grades of absent, trace, mild, moderate, or severe.

    Time frame: From Baseline (Day1) to the End of Safety Follow Up (up to 3 years and 10 months)

  17. Incidence of treatment-emergent Doppler ECHO results meeting the FDA case definition of PAH (defined as a PASP >35mmHg) from baseline to end of safety follow up

    ECHO readings related to pulmonary arterial hypertenstion (PAH) will be reported based on Pulmonary artery systolic pressure (PASP).

    Time frame: From Baseline (Day1) to the End of Safety Follow Up (up to 3 years and 10 months)

07

Study locations

40 of 40 sites recruiting
  • Ep0247 21010
    Little Rock, Arkansas 72202, United States
    Recruiting
  • Ep0247 21009
    Miami, Florida 33155, United States
    Recruiting
  • Ep0247 21011
    Orlando, Florida 32806, United States
    Recruiting
  • Ep0247 21007
    Atlanta, Georgia 30322, United States
    Recruiting
  • Ep0247 21003
    Philadelphia, Pennsylvania 19104-4318, United States
    Recruiting
  • Ep0247 21005
    Houston, Texas 77030, United States
    Recruiting
  • Ep0247 21013
    Irving, Texas 75062, United States
    Recruiting
  • Ep0247 21004
    Seattle, Washington 98105, United States
    Recruiting
  • Ep0247 11001
    Brussels, Belgium
    Recruiting
  • Ep0247 11002
    Edegem, Belgium
    Recruiting
  • Ep0247 12005
    Brest, France
    Recruiting
  • Ep0247 12003
    Bron, France
    Recruiting
  • Ep0247 12004
    Marseille, France
    Recruiting
  • Ep0247 12001
    Paris, France
    Recruiting
  • Ep0247 12006
    Paris, France
    Recruiting
  • Ep0247 13001
    Tbilisi, Georgia
    Recruiting
  • Ep0247 13002
    Tbilisi, Georgia
    Recruiting
  • Ep0247 14001
    Vogtareuth, Germany
    Recruiting
  • Ep0247 15001
    Budapest, Hungary
    Recruiting
  • Ep0247 15002
    Debrecen, Hungary
    Recruiting
  • Ep0247 16001
    Ramat Gan, Israel
    Recruiting
  • Ep0247 17003
    Genova, Italy
    Recruiting
  • Ep0247 17001
    Milan, Italy
    Recruiting
  • Ep0247 17008
    Naples, Italy
    Recruiting
  • Ep0247 17002
    Pisa, Italy
    Recruiting
  • Ep0247 17006
    Troina, Italy
    Recruiting
  • Ep0247 43005
    Chiyoda-ku, Japan
    Recruiting
  • Ep0247 43004
    Kodaira, Japan
    Recruiting
  • Ep0247 43001
    Kurume, Japan
    Recruiting
  • Ep0247 43006
    Musashimurayama-shi, Japan
    Recruiting
  • Ep0247 43002
    Osaka, Japan
    Recruiting
  • Ep0247 43003
    Setagaya-ku, Japan
    Recruiting
  • Ep0247 19003
    Gdansk, Poland
    Recruiting
  • Ep0247 19002
    Krakow, Poland
    Recruiting
  • Ep0247 11101
    Madrid, Spain
    Recruiting
  • Ep0247 11105
    Madrid, Spain
    Recruiting
  • Ep0247 11103
    Málaga, Spain
    Recruiting
  • Ep0247 11102
    Seville, Spain
    Recruiting
  • Ep0247 11303
    Manchester, United Kingdom
    Recruiting
  • Ep0247 11304
    Nottingham, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Feb 2029, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Mar 31, 2026
StartActual
Jul 14, 2026
Primary completionEst.
Feb 6, 2029
CompletionEst.
Aug 29, 2031
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
17 sites added — first sites in Germany, Georgia, Israel and United Kingdom
Show 17 added (3 France, 2 United States, 2 Italy, 2 Georgia, 2 United Kingdom, 1 Germany, 1 Spain, 1 Belgium, 1 Israel, 1 Japan, 1 Poland)
  • Ep0247 21003 · Philadelphia, United States
  • Ep0247 21004 · Seattle, United States
  • Ep0247 12003 · Bron, France
  • Ep0247 12004 · Marseille, France
  • Ep0247 12001 · Paris, France
  • Ep0247 14001 · Vogtareuth, Germany
  • Ep0247 17003 · Genova, Italy
  • Ep0247 17001 · Milan, Italy
  • Ep0247 11101 · Madrid, Spain
  • Ep0247 13001 · Tbilisi, Georgia
  • Ep0247 11002 · Edegem, Belgium
  • Ep0247 13002 · Tbilisi, Georgia
  • Ep0247 16001 · Ramat Gan, Israel
  • Ep0247 43005 · Chiyoda-ku, Japan
  • Ep0247 19003 · Gdansk, Poland
  • Ep0247 11303 · Manchester, United Kingdom
  • Ep0247 11304 · Nottingham, United Kingdom
across 3 updates, Oct 2, 2026 – Nov 2, 2026
Show all 3 updates
  1. Nov 2, 2026
    7 sites added — first sites in Israel and United Kingdom
    Show 7 added (2 United Kingdom, 1 Belgium, 1 Georgia, 1 Israel, 1 Japan, 1 Poland)
    • Ep0247 11002 · Edegem, Belgium
    • Ep0247 13002 · Tbilisi, Georgia
    • Ep0247 16001 · Ramat Gan, Israel
    • Ep0247 43005 · Chiyoda-ku, Japan
    • Ep0247 19003 · Gdansk, Poland
    • Ep0247 11303 · Manchester, United Kingdom
    • Ep0247 11304 · Nottingham, United Kingdom
  2. Oct 15, 2026
    1 site added — first site in Georgia
    Show site
    • Ep0247 13001 · Tbilisi, Georgia
    + 1 other change: verification date
  3. Oct 2, 2026
    9 sites added — first site in Germany
    Show 9 added (3 France, 2 United States, 2 Italy, 1 Germany, 1 Spain)
    • Ep0247 21003 · Philadelphia, United States
    • Ep0247 21004 · Seattle, United States
    • Ep0247 12003 · Bron, France
    • Ep0247 12004 · Marseille, France
    • Ep0247 12001 · Paris, France
    • Ep0247 14001 · Vogtareuth, Germany
    • Ep0247 17003 · Genova, Italy
    • Ep0247 17001 · Milan, Italy
    • Ep0247 11101 · Madrid, Spain

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07503444
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Jul 14, 2026
Primary completion
Feb 6, 2029 (estimated)
Completion
Aug 29, 2031 (estimated)
Last update
Nov 2, 2026

Study contacts

UCB Cares
Contact
ucbcares@ucb.com
+18445992273
UCB Cares
Contact
UCBCares@ucb.com
0018445992273
UCB Cares
study director · 0018445992273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenfluramine

Start the discussion